These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3531952)

  • 21. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
    Brandt SJ; Peters WP; Atwater SK; Kurtzberg J; Borowitz MJ; Jones RB; Shpall EJ; Bast RC; Gilbert CJ; Oette DH
    N Engl J Med; 1988 Apr; 318(14):869-76. PubMed ID: 3281007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma.
    McElwain TJ; Hedley DW; Gordon MY; Jarman M; Millar JL; Pritchard J
    Exp Hematol; 1979; 7 Suppl 5():360-71. PubMed ID: 400698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
    Devereaux S; Linch DC; Gribben JG; McMillan A; Patterson K; Goldstone AH
    Bone Marrow Transplant; 1989 Jan; 4(1):49-54. PubMed ID: 2647187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
    Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer.
    Coombes RC; Buckman R; Forrester JA; Shepherd V; O'Hare MJ; Vincent M; Powles TJ; Neville AM
    Cancer Res; 1986 Aug; 46(8):4217-20. PubMed ID: 3524802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation.
    Neidhart J; Mangalik A; Kohler W; Stidley C; Saiki J; Duncan P; Souza L; Downing M
    J Clin Oncol; 1989 Nov; 7(11):1685-92. PubMed ID: 2478670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
    Taylor KM; Jagannath S; Spitzer G; Spinolo JA; Tucker SL; Fogel B; Cabanillas FF; Hagemeister FB; Souza LM
    J Clin Oncol; 1989 Dec; 7(12):1791-9. PubMed ID: 2479719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy.
    Spitzer G; Deisseroth A; Ventura G; Jagannath S; Fogel B; Taylor K; Huan S; Dunphy F; Dicke K; Souza L
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():249-59; discussion 259-61. PubMed ID: 1691246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.
    Østby I; Rusten LS; Kvalheim G; Grøttum P
    J Math Biol; 2003 Aug; 47(2):101-36. PubMed ID: 12883857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
    Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
    Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.
    To LB; Roberts MM; Haylock DN; Dyson PG; Branford AL; Thorp D; Ho JQ; Dart GW; Horvath N; Davy ML
    Bone Marrow Transplant; 1992 Apr; 9(4):277-84. PubMed ID: 1350938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
    Awedan AA
    Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
    Laporte JP; Yeshurun M; Fouillard L; Labopin M; Cailliot C; Lesage S; Isnard F; Najman A; Gorin NC
    Leukemia; 2004 Oct; 18(10):1717-21. PubMed ID: 15295607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.
    Grigg A; Begley CG; Juttner CA; Szer J; To LB; Maher D; McGrath KM; Morstyn G; Fox RM; Sheridan WP
    Bone Marrow Transplant; 1993; 11 Suppl 2():23-9. PubMed ID: 8334435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
    Koeppler H; Pflueger KH; Seitz R; Havemann K
    Onkologie; 1989 Dec; 12(6):277-9. PubMed ID: 2696912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain.
    Honess DJ; Bleehen NM
    Br J Cancer; 1982 Aug; 46(2):236-48. PubMed ID: 6758828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
    Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
    Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous nonfrozen bone marrow transplantation after intensive chemotherapy: a pilot study.
    Robinson WA; Hartmann DW; Mangalik A; Morton N; Joshi JH
    Acta Haematol; 1981; 66(3):145-53. PubMed ID: 6795872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.